



## Recent Research on Neutralizing Antibody Response to SARS-CoV-2 Variants

Guest Editor:

**Dr. Chloé Dimeglio**

Virology Laboratory, Toulouse  
University Hospital, 31300  
Toulouse, France

Deadline for manuscript  
submissions:

**closed (6 August 2025)**

### Message from the Guest Editor

Dear Colleagues,

COVID-19 continues to spread globally. Despite vaccination boosting, the risk of getting infected or reinfected with SARS-CoV-2 remains due to the emergence of viral variants. Often, these variants may evade naturally acquired or vaccine-induced immunity. Therefore, it is essential to study the relationship between genetic diversity, antibody response, and the evolution of SARS-CoV-2. The aim of this Special Issue is to evaluate recent research on the neutralizing antibody response to SARS-CoV-2 variants. We welcome original research articles and reviews. Research areas may include but are not limited to SARS-CoV-2 and vaccines, SARS-CoV-2 and natural infection, immunity mechanisms, competition between variants, vaccine escape, and SARS-CoV-2 dynamics.

We look forward to receiving your contributions.

Dr. Chloé Dimeglio

*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ger Rijkers

Department of Health, Cognition  
and Behavior, University College  
Roosevelt, 4331 CB Middelburg,  
The Netherlands

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

Vaccines Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)